Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 308Lung Neoplasms 70Neoplasms 50Neoplasm Metastasis 33Parkinson Disease 4, Autosomal Dominant Lewy Body 20Colorectal Neoplasms 20Carcinoma 20Mesothelioma 15Breast Neoplasms 15Mesothelioma, Malignant 13Small Cell Lung Carcinoma 11Melanoma 10Adenocarcinoma 10Neoplasms by Site 9Adenocarcinoma of Lung 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Lung Diseases 7Thoracic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Non-Squamous Non-Small Cell Lung Cancer 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Respiratory Tract Diseases 5Recurrence 5Rectal Neoplasms 5Neoplasms by Histologic Type 5NSCLC 5Head and Neck Neoplasms 5Endometrial Neoplasms 5

Interventions

trametinib 1spartalizumab 1pembrolizumab 1nazartinib 1canakinumab 1Pemetrexed 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ductal × Pemetrexed × Clear all
NCT00106002 2009-06-01

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Eli Lilly and Company

Phase 2 Completed
37 enrolled 9 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡